AUTHOREA
Log in
Sign Up
Browse Preprints
LOG IN
SIGN UP
Essential Site Maintenance
: Authorea-powered sites will be updated circa 15:00-17:00 Eastern on Tuesday 5 November.
There should be no interruption to normal services, but please contact us at
[email protected]
in case you face any issues.
Bo Chen
Public Documents
1
Anti-CD19 CAR T as a feasible and safe therapy for refractory/relapsed mixed phenotyp...
Xiangqun Li
and 12 more
January 20, 2022
Mixed phenotype acute leukemia (MPAL) is a relatively rare and heterogeneous group of diseases, which account for 2-5% of leukemia. So far, no optimal treatment regimens have been established for MPAL patients. CD19 chimeric antigen receptor T (CAR T) therapy have shown remarkable efficacy in B-ALL patients. In this study, 5 MPAL patients received CD19 CAR T cell infusion and 3 out of 5 patients (60%) achieved complete response (CR). 2 of 5 patients had only mild cytokine release syndrome (CRS). Neurotoxicity was not observed. Our data indicate that CD19 CAR T therapy is safe and effective for majority refractory/relapsed (r/r) MPAL patients.